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Abstract 
Hepatocellular carcinoma (HCC) is a common, aggressive malignancy that usually 
develops in a background of liver cirrhosis. Practice guidelines recommend screening 
of cirrhotic patients with ultrasound and more detailed imaging (computed tomography 
or magnetic resonance imaging) if abnormalities are detected. The utility of alpha-
fetoprotein levels in HCC surveillance is controversial. Although HCC risk differs by 
etiology of cirrhosis, screening and surveillance guidelines are uniform after cirrhosis is 
established. We report a case of rapidly progressive HCC occurring in a cirrhotic patient 
with multiple unique risk factors for neoplasia, detected by a rising alpha-fetoprotein 
level without imaging features of liver cancer. 
Introduction 
Hepatocellular carcinoma (HCC) is common in patients with cirrhosis. Practice 
guidelines issued by the American Association for the Study of Liver Diseases (AASLD) 
recommend screening for HCC with abdominal ultrasound every 6 months, with 
abnormalities prompting additional imaging with triple-phase helical computed 
tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) [1]. If a small 
nodule is detected (less than 1 cm in diameter), the imaging study that first detected the 
lesion is repeated every 3–6 months, with monitoring of the serum alpha-fetoprotein 
(AFP) level discouraged due to poor specificity. Although the risk of HCC varies with 
different etiologies of cirrhosis, HCC screening and surveillance recommendations are 
uniform once cirrhosis is established.  Case Rep Gastroenterol 2011;5:565–568 
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We report a case of advanced HCC, undetected during routine surveillance imaging of 
a small liver nodule, occurring in a cirrhotic patient with multiple unique risk factors for 
neoplasia. 
Case Report 
A 41-year-old man with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) 
co-infection and cirrhosis was evaluated. With tenofovir and emtricitabine, viral copies of HIV 
and HBV were undetectable. Although cirrhosis was classified as decompensated due to the 
identification of large esophageal varices, he had no ascites or encephalopathy and fulfilled the criteria 
for Child-Pugh class A cirrhosis with Model for End-Stage Liver Disease score 9. CT obtained 2 years 
before presentation showed an 8-mm nodule in the hepatic dome with arterial enhancement but 
without portal venous phase washout, and monitoring with CT or MRI every 6 months did not show 
enlargement or a change in the pattern of contrast enhancement. AFP ranged from 11 to 16 ng/ml. The 
liver nodule was thought to be of benign etiology. 
At presentation the patient reported 1 week of malaise, headache, and nausea. On examination, 
he was alert and afebrile, with a heart rate of 94 bpm and a blood pressure of 149/89 mm Hg. 
Cardiopulmonary, neurologic, and abdominal examinations were unremarkable; he had no jaundice, 
ascites, or asterixis. CT was obtained and demonstrated no change in the hepatic dome nodule and no 
new lesions (fig. 1a). Laboratory studies revealed white blood cells 5,300/ml, platelets 107,000/ml, 
bilirubin 1.1 mg/dl, international normalized ratio 1.2, and AFP 24,437 ng/ml. The elevated AFP level 
prompted a second imaging study, contrast-enhanced MRI, which demonstrated a 10-cm infiltrative 
mass in the right hepatic lobe with arterial phase enhancement and portal venous phase washout, 
consistent with HCC (fig. 1b). Tumor thrombus was identified in the right portal vein. Based on this 
vascular invasion, Barcelona Clinic Liver Cancer stage C HCC was diagnosed. The patient was deemed 
to have good performance status (Eastern Cooperative Oncology Group score 1), and treatment for 
advanced HCC was initiated with sorafenib [2, 3]. 
Discussion 
The ability to diagnose HCC without a need for biopsy is unique among cancers, and 
is facilitated by distinct radiographic features and, more controversially, elevated AFP 
levels [1]. A minority of patients demonstrate robust AFP production, but when present, 
AFP levels >200 ng/ml are specific for HCC, and levels >500 ng/ml correlate with tumor 
size [4]. The sensitivity of CT for HCC detection is 61–74%, versus 76–85% for magnetic 
resonance angiography or MRI using gadoxetate disodium contrast [5, 6]. Recognizing 
this limited sensitivity, the AASLD practice guidelines recommend liver biopsy or a 
second dynamic imaging study when a first study shows a suspicious mass >1 cm in 
diameter. A lesion <1 cm, if stable over time, is deemed a cirrhotic nodule, and 
multimodality imaging or histologic evaluation is discouraged. HCC risk varies with the 
underlying etiology of liver disease, but recommendations for screening and surveillance 
in cirrhosis do not.  
HIV/HBV co-infection is associated with development of advanced liver disease, 
elevated liver-related mortality, and high rates of hepatocarcinogenesis [7]. HCC is more 
frequent in co-infected than HBV mono-infected patients with cirrhosis, and progresses 
more rapidly after it develops [8]. HIV-positive patients with HCC are younger, more apt 
to have advanced or multiple tumors, and more frequently symptomatic at presentation. 
Since the efficacy of surveillance is inversely proportional to the rate of tumor growth, 
accelerated growth of HCC in HIV/HBV co-infection may undermine the benefit of 
routine surveillance [1, 9]. In this high-risk group, the efficacy and cost-effectiveness of Case Rep Gastroenterol 2011;5:565–568 
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more frequent surveillance, or combined surveillance with multimodality imaging or 
the addition of AFP monitoring, has not been evaluated. Elevated HBV viral copies 
(>2,000 IU/ml), low CD4+ count (<100/mm
3), and family history of HCC have been 
postulated as risk stratification criteria to identify HIV/HBV co-infected patients who 
may warrant intensive surveillance [9].  
Conclusion 
Our case illustrates an alarming scenario in which practice guidelines for liver 
cancer detection would have missed a diagnosis of advanced HCC, delaying treatment. 
HIV/HBV co-infection portends a poor prognosis in chronic liver disease and an 
increased risk of rapidly progressive HCC. Though the optimal HCC surveillance strategy 
in the HIV/HBV co-infected patient remains undefined, clinicians must be aware that 
among patients with cirrhosis, co-infection is the apex of HCC risk. Despite persistent 
stable size of a small nodule on a first dynamic imaging study, patients with especially 
high-risk etiologies of liver disease warrant heightened concern for a malignant process. 
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Fig. 1. a CT revealing an 8-mm liver nodule (arrow). b Contrast-enhanced MRI showing a 10 × 8 cm 
enhancing mass in the right hepatic lobe, not seen with CT (arrowheads). 
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